Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2016-07-29 08:00 |
BIOPHYTIS receives approval of bpifrance for an innovation loan of €1.1M to f…
|
English | 495.0 KB | ||
| 2016-07-25 19:00 |
BIOPHYTIS : approbation de lancer l’étude clinique de pharmacocinétique de …
|
French | 112.5 KB | ||
| 2016-07-25 19:00 |
BIOPHYTIS receives authorization to start Sarconeos pharmacokinetics study (SAR…
|
English | 108.6 KB | ||
| 2016-06-10 19:00 |
Biophytis : Assemblée Générale Mixte du 10 juin 2016
|
French | 109.8 KB | ||
| 2016-06-10 19:00 |
Biophytis : Combined General Shareholders’ Meeting held on June 10, 2016
|
English | 107.2 KB | ||
| 2016-05-31 19:05 |
BIOPHYTIS participera à BIO International Convention à San Francisco
|
French | 454.5 KB | ||
| 2016-05-31 19:05 |
BIOPHYTIS to attend BIO International Convention in San Francisco
|
English | 447.5 KB | ||
| 2016-05-05 00:00 |
BIOPHYTIS : Assemblée Générale convoquée le 10 juin 2016
|
French | 103.7 KB | ||
| 2016-04-29 19:05 |
BIOPHYTIS dévoile une stratégie de développement clinique ambitieuse aux Etats-…
|
French | 153.7 KB | ||
| 2016-04-29 19:05 |
BIOPHYTIS unveils its clinical development strategy in the United States, as it…
|
English | 144.5 KB | ||
| 2016-04-12 08:20 |
BIOPHYTIS : présentations aux congrès ICFSR (Philadelphie) et ARVO (Seattle)
|
French | 133.2 KB | ||
| 2016-04-12 08:20 |
BIOPHYTIS to present results at ICFSR (Philadelphia) and ARVO (Seattle)
|
English | 126.2 KB | ||
| 2016-03-17 18:30 |
BIOPHYTIS : résultats annuels 2015
|
French | 321.4 KB | ||
| 2016-03-17 18:30 |
BIOPHYTIS : 2015 annual results
|
English | 318.8 KB | ||
| 2016-03-11 07:20 |
BIOPHYTIS annonce avoir reçu l’avis favorable de l’AFMPS (Belgique) sur le plan…
|
French | 116.5 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
